BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 12811626)

  • 1. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
    Kitatani K; Nakatsuka K; Naka H; Miki T; Morii H; Nishizawa Y
    J Bone Miner Metab; 2003; 21(4):217-24. PubMed ID: 12811626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of methods for measuring serum and urinary markers of bone metabolism in cats.
    DeLaurier A; Jackson B; Pfeiffer D; Ingham K; Horton MA; Price JS
    Res Vet Sci; 2004 Aug; 77(1):29-39. PubMed ID: 15120950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis.
    Hasegawa J; Nagashima M; Yamamoto M; Nishijima T; Katsumata S; Yoshino S
    J Rheumatol; 2003 Mar; 30(3):474-9. PubMed ID: 12610804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women.
    Yasui T; Miyatani Y; Tomita J; Yamada M; Uemura H; Miura M; Irahara M
    Gynecol Endocrinol; 2006 Aug; 22(8):455-9. PubMed ID: 17012108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis.
    Seibel MJ; Cosman F; Shen V; Gordon S; Dempster DW; Ratcliffe A; Lindsay R
    J Bone Miner Res; 1993 Jul; 8(7):881-9. PubMed ID: 8352070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of age, menopause and osteoporosis on free, peptide-bound and total pyridinium crosslink excretion.
    Del Campo MT; González-Casaus ML; Aguado P; Bernad M; Carrera F; Martínez ME
    Osteoporos Int; 1999; 9(5):449-54. PubMed ID: 10550465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
    Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
    Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
    Okabe R; Inaba M; Nakatsuka K; Miki T; Naka H; Moriguchi A; Nishizawa Y
    J Bone Miner Metab; 2004; 22(2):127-31. PubMed ID: 14999523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary bone resorption markers (deoxypyridinoline and C-terminal telopeptide of type I collagen) in healthy persons, postmenopausal osteoporosis and patients with type I diabetes.
    Fassbender WJ; Gödde M; Brandenburg VM; Usadel KH; Stumpf UC
    Adv Med Sci; 2009; 54(1):1-6. PubMed ID: 19482729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid bone loss is associated with increased levels of biochemical markers.
    Ross PD; Knowlton W
    J Bone Miner Res; 1998 Feb; 13(2):297-302. PubMed ID: 9495524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.
    Robins SP; Woitge H; Hesley R; Ju J; Seyedin S; Seibel MJ
    J Bone Miner Res; 1994 Oct; 9(10):1643-9. PubMed ID: 7817812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary osteocalcin and other markers of bone metabolism: the effect of risedronate therapy.
    Kumm J; Ivaska KK; Rohtla K; Vaananen K; Tamm A
    Scand J Clin Lab Invest; 2008; 68(6):459-63. PubMed ID: 18609099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
    Trento LK; Pietropolli A; Ticconi C; Gravotta E; De Martino MU; Fabbri A; Piccione E
    J Obstet Gynaecol Res; 2009 Feb; 35(1):152-9. PubMed ID: 19215563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Urinary excretion of free and total deoxypyridinoline during secondary hyperparathyroidism in the elderly. Comparison of chromatographic (HPLC) and immunoenzymatic (Pyrilinks-D) methods].
    Meddah B; Brazier M; Kamel S; Maamer M; Samson L; Desmet G; Sebert JL
    Ann Biol Clin (Paris); 1996; 54(10-11):353-8. PubMed ID: 9092303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis.
    Verit FF; Geyikli I; Yazgan P; Celik A
    Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].
    Nakamura T; Maekawa S; Morinobu S; Morinobu A; Koshiba M; Yamauchi M; Sugimoto T; Kumagai S
    Ryumachi; 2002 Aug; 42(4):666-75. PubMed ID: 12355861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers of bone resorption--measurement in serum, plasma or urine?
    Huber F; Traber L; Roth HJ; Heckel V; Schmidt-Gayk H
    Clin Lab; 2003; 49(5-6):203-7. PubMed ID: 15285175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
    Denk E; Hillegonds D; Hurrell RF; Vogel J; Fattinger K; Häuselmann HJ; Kraenzlin M; Walczyk T
    J Bone Miner Res; 2007 Oct; 22(10):1518-25. PubMed ID: 17576167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.